Lower starting doses of sorafenib feasible for advanced thyroid cancer
A new study published in The Oncologistjournal shows that a subset of patients with advanced differentiated thyroid cancer (DTC) and multiple comorbidities in which full-dose sorafenib is considered unsafe can initiate treatment with sorafenib at lower starting doses without adversely affecting efficacy or tolerability compared with full-dose sorafenib. A team of researchers led by Ramona Dadu, MD, at the MD Anderson Cancer Center in Houston, TX, performed a retrospective analysis to evaluate the relationship between sorafenib starting doses and first-line treatment tolerability and efficacy.
First study tracking stem cell treatments for children with spinal cord injuries shows potential benefit
Previous studies have shown that multiple stem cell implantations might assist adults suffering from complete spinal cord injuries (SCI). Now a groundbreaking study released today in STEM CELLS Translational Medicine shows for the first time that children with SCI might benefit, too.
PET/CT and biomarkers predict treatment response in metastatic colon cancer
A new study published online today in The Oncologist journal shows that an assessment of metabolic response in patients with metastatic colon cancer (mCC) treated with a single course of chemotherapy could predict the downstream efficacy of the treatment. A team of researchers from various institutions in Denmark, led by Bodil Engelmann, MD, at Næstved Hospital in Copenhagen, performed a prospective, monocentric study to determine the predictive value of a number of established biomarkers as well as the results of 2-deoxy-2-[18F]fluoro-D-glucose (FDG) positron-emission tomography/computed tomography (PET/CT) in the early response of mCC to treatment with widely used chemotherapeutic drugs.
Diabetes drug improves outcomes for cancer patients
November 20, 2013 - A new study published online in The Oncologist journal shows that cancer patients with concurrent type 2 diabetes treated with metformin have a greater overall survival rate compared with patients taking other glucose-lowering medications. A team of researchers led by Ming Yin, MD, at Geisinger Medical Center in Danville, PA, performed a meta-analysis to evaluate the association of metformin treatment and both overall and cancer-specific survival.
Protein found in fat-derived stem cells could halt age-related retinal damage
November 14, 2013 – A team of researchers from Gifu Pharmaceutical University and Gifu University in Japan has published results demonstrating that a type of protein found in stem cells taken from adipose (fat) tissue can reverse and prevent age-related, light-induced retinal damage in a mouse model, offering hope for those faced with permanent vision loss.
- Protein found in fat-derived stem cells could halt age-related retinal damage
- Revisiting prevention of blood clots in chemotherapy patients
- MAPCs bring lasting improvements after brain injury, pre-clinical study finds
- New way to grow neural stem cells could accelerate therapy development for brain injuries and diseases
Page 1 of 2